The Aicardi-Goutieres Syndrome (AGS) drugs in development market research report provides comprehensive information on the therapeutics under development for Aicardi-Goutieres Syndrome (AGS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Aicardi-Goutieres Syndrome (AGS). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Aicardi-Goutieres Syndrome (AGS) and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Aicardi-Goutieres Syndrome (AGS) by seven companies/universities/institutes. The top development phase for Aicardi-Goutieres Syndrome (AGS) is preclinical with three drugs in that stage. The Aicardi-Goutieres Syndrome (AGS) pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Aicardi-Goutieres Syndrome (AGS) pipeline products market are: Icagen, Gilead Sciences and Eli Lilly and Co.
The key targets in the Aicardi-Goutieres Syndrome (AGS) pipeline products market include Cyclic GMP-AMP Synthase, Reverse Transcriptase, and Tyrosine Protein Kinase JAK1.
The key mechanisms of action in the Aicardi-Goutieres Syndrome (AGS) pipeline product include Reverse Transcriptase Inhibitor with two drugs in Phase II. The Aicardi-Goutieres Syndrome (AGS) pipeline products include one routes of administration with the top ROA being Oral and two key molecule types in the Aicardi-Goutieres Syndrome (AGS) pipeline products market including Small Molecule, and Biologic.
Aicardi-Goutieres Syndrome (AGS) overview
Aicardi-Goutieres syndrome which is also known as pseudotoxoplasmosis , is an inherited disease that mainly affects the brain, immune system, and the skin. Loss of white matter in the brain (leukodystrophy) and calcification in the brain leads to an early-onset encephalopathy that usually results in physical disability.
For a complete picture of Aicardi-Goutieres Syndrome (AGS)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
